MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?
Moderna shares gained 3% following better-than-expected Q3 2026 earnings and raised full-year revenue guidance to 15-25% growth, driven by stronger international COVID-19 vaccine sales. The company's oncology pipeline, particularly its personalized cancer therapy intismeran developed with Merck, showed promising phase III results with a 42% reduction in recurrence or death risk. Despite premium valuation and ongoing cash burn concerns, Moderna maintains a Zacks Rank #2 (Buy) rating, supported by expanding respiratory vaccine portfolio and oncology opportunities.
